Denmark-based Zealand Pharma (Nasdaq: ZEAL) reported positive topline results from the Phase II ZUPREME-2 trial of petrelintide, a once-weekly injectable amylin analog being developed with Roche for chronic weight management. The trial met its primary endpoint, with participants receiving petrelintide achieving up to 9.2% mean weight loss at Week 28 versus 2.0% for placebo in adults with overweight or obesity and type 2 diabetes.
The 220-patient study demonstrated statistically significant weight loss across all three petrelintide dose groups, ranging from 7.4% to 9.2%. Treatment also produced placebo-adjusted HbA1c reductions of 0.61–0.88 percentage points. Gastrointestinal adverse events were mostly mild, with discontinuation due to these events occurring in 1.9% of petrelintide recipients versus 1.7% on placebo. No unexpected safety signals were reported.
The findings build on positive results from the Phase II ZUPREME-1 trial in people without type 2 diabetes, where petrelintide achieved up to 10.7% mean weight loss at Week 42, compared with 1.7% for placebo. Results from that study were published in The Lancet Diabetes & Endocrinology in September 2026.